Colombian Journal of Anesthesiology Colombian Journal of Anesthesiology
Rev Colomb Anestesiol 2012;40:213-23 - Vol. 40 Num.3 DOI: 10.1016/j.rcae.2012.05.005
Review
Management of non-obstetric pain during pregnancy. Review article
Manejo del dolor no obstétrico durante el embarazo. Artículo de revisión
Roberto Rivera Díaza,??, , , Adriana Lopera Riverab
a Professor of Anesthesia and Pain Subspecialty, CES University, Colombian Institute of Pain, Medellín, Colombia
b Anesthesia Resident, CES University, Medellín, Colombia
Received 29 May 2011, Accepted 04 April 2012
Abstract
Introduction

In pregnancy, women experience pain for reasons other than labor or delivery. Painful syndromes may occur during pregnancy, or chronic pain may become more acute, and patients should be offered treatment, always bearing in mind maternal and fetal safety.

Objective

To conduct a review of the scientific literature on the management of non-obstetric pain during pregnancy and the potential implications of the different pharmacological and interventional therapies available.

Materials and methods

Non-systematic review in the following databases: Medline, Pubmed, FDA and Drugs with a search of relevant articles in English.

Results

The articles related to the various types of therapies for pain management during pregnancy were selected.

Conclusion

The comprehensive approach to the management of conditions that may produce pain during pregnancy requires the use of medications that are not always 100% safe. Treatment must be inter-disciplinary and humanized, and consider the implications for the mother and fetus, optimizing, whenever possible, non-pharmacological therapeutic options.

Resumen
Introducción

La mujer embarazada experimenta dolor por causas diferentes al trabajo de parto o al parto. Durante el embarazo pueden presentarse síndromes dolorosos agudos o se agudizan dolores crónicos que deben ser tratados, asegurándose siempre de mantener la seguridad para la madre y el feto.

Objetivo

Realizar una revisión de la literatura científica acerca del manejo del dolor de causas no obstétricas durante el embarazo, y las posibilidades e implicaciones de las diferentes terapias disponibles tanto farmacológicas como intervencionistas.

Materiales y métodos

Revisión no sistemática. Se consultaron las siguientes bases de datos: Medline, Pubmed, FDA y Drugs, en búsqueda de artículos en inglés relevantes.

Resultados

Se seleccionaron los artículos correspondientes a los diferentes tipos de terapia disponibles en el manejo del dolor durante el embarazo.

Conclusión

El manejo integral de las patologías que pudieran generar dolor durante el embarazo requiere del uso de medicamentos que no siempre son 100% seguros. Su tratamiento debe ser interdisciplinario y humanizado, teniendo en cuenta las implicaciones para la madre y el feto, y mientras sea posible, optimizando alternativas terapéuticas no farmacológicas.

Keywords
Pain, Pregnancy, Labor, Acute pain, Analgesics
Palabras clave
Dolor, Embarazo, Trabajo de parto, Dolor agudo, Analgésicos
Introduction

Pregnancy involves physiological and body changes that favor the onset of painful diseases or may intensify pre-existing painful conditions. Even though non-obstetrical pain in pregnancy is common, in our search of pain management of pregnant women, we found abundant literature focusing on analgesia for labor, while pain management during the rest of gestation has been neglected.

Most cases of acute pain in pregnancy are treated, first of all, by ruling out an obstetric cause. The use of common analgesics, a few days of rest, and patient education about pain and the effect on the fetus, are usually enough in terms of treatment.

Consequently, the problem arises when pain does not improve, becomes chronic and, worse still, when the patient with a history of chronic pain becomes pregnant, because the therapeutic armamentarium is immediately reduced, either because of the availability of safe drugs or because of lack of knowledge of the problem.

The most important implication is the potential risk of toxicity or teratogenicity of the pharmacological agents or the interventions used for pain relief.

The following are some considerations to bear in mind in pregnant women who complain of pain.

Migraine

Migraine of onset during pregnancy is rare and occurs only in 3% of patients, typically during the first trimester.1

However, it is common to find pregnant women with a past history of migraine. In general, migraine improves during pregnancy, in particular during the first trimester. Studies report an improvement range of 43–86%, depending on the type of migraine; for example, there is a higher rate of improvement in cases of menstruation-associated migraine.2

Initial management must focus on non-pharmacological therapies such as relaxation exercises, acupuncture, biofeedback and behavioral cognitive therapy. When those therapies fail, the first line drug treatment is paracetamol.

Triptanes must be avoided in the third trimester because of the slight increase in the risk of uterine atony and peripartum hemorrhage. The literature has not demonstrated or ruled out a relationship of teratogenicity.

Low-dose ergot derivatives have a high teratogenic risk, and high doses may provoke uterine contractions and miscarriage.

Caffeine may produce intra-uterine growth retardation (IUGR), fetal death and premature delivery.

Beta-blockers have not been shown to be teratogenic. Low fetal weight has been reported as a result of a moderate reduction of placental blood flow from low maternal cardiac output. When used during the peripartum period, it is important to pay attention to the newborn because of the risk of inducing bradycardia, hypotension, hypoglycemia, hypothermia, respiratory distress and apnea. Of this group of drugs, propranolol, metoprolol, nadolol and timolol are considered category C, while atenolol is considered category D.3

Angiotensin converting enzyme inhibitors are considered toxic for the fetus and should not be used during pregnancy. They may cause limb contractures, craniofacial malformations, pulmonary hypoplasia, renal defects, oligohydramnios, IUGR, patent ductus arteriosus, anuria, neonatal hypotension and death.4

Muscle-skeletal pain

Back pain may occur in two-thirds of all pregnancies, and pelvic pain in one-fifth.5 The physiological changes that take place during this period, including fluid retention, joint laxity and displacement of the center of gravity, explain the high prevalence of these conditions during pregnancy.6 The two types of pain worsen sleep disorders, and affect work and the woman's daily life.5,7

The most frequent causes of muscle-skeletal pain include upper lumbar pain (10%), lower lumbar pain (41%) and sacroiliitis (48%).7 Pubic symphysis pain is less frequent, although it is more disabling.8,9

In pregnancy-related posterior pelvic pain (PRPP), laxity of the sacroiliac joints has been proposed as a cause. Some propose the asymmetric laxity of the joint. Relaxin, previously implicated as a cause of this form of pain, has been ruled out in recent research.6,10,11

Fortunately, the frequency of disc disease is not higher in pregnancy, but nerve root compression and the presence of a cauda equina (1:10,000) may require neurosurgical or interventional procedures such as percutaneous discectomies or epidural injections,12 with the consequences that they may bring both for the mother as well as the fetus.

In 2008, there was a Cochrane review of the randomized controlled studies available for assessing response to interventions for the prevention and treatment of pelvic and back pain during pregnancy. The interventions described included exercises in the water, pelvic belts, the Ozzlo cushion, physical therapy, acupuncture, TENS and acetaminophen. The conclusion was that no treatment is 100% effective, and that the combination of standard prenatal care together with exercise led to a slight reduction in the pain reported by the patients.5,13–15 Moreover, it was determined that pain worsened as gestation advanced.

Neuropathic pain

The most common conditions that produce neuropathic pain in pregnant women include carpal tunnel syndrome, meralgia paresthetica, low intercostal nerve compression, and pain in the scar of a previous cesarean section.

In general, carpal tunnel syndrome in pregnancy has been attributed to physiological changes, among which fluid retention favors nerve trapping, especially during the second trimester. The treatment includes using splints during the night, physical therapy, local anesthetic infiltration and slow-release steroids and, in extreme cases, surgical decompression.15–17 Fortunately, symptoms usually go away after delivery in most cases.

Pregnancy, together with obesity, diabetes and certain postures favors meralgia paresthetica. Local infiltration of steroids and anesthetics, physical therapy, surgical decompression, and expectant management have all been described.11,12

Distended abdominal tissues could also be a source of pain because of traction on subcostal nerves and previous C-section scars.14,15

The results of the Collaborative Perinatal Project suggest that fetal risk is minimal when low-dose single injections of local anesthetics and slow-release steroids are used during the second or the third trimester.18

Women with pre-existing chronic pain

In the United States, at least 50% of women become pregnant unexpectedly and, in Colombia, figures are not very different. This creates a risk for the fetus, given that exposure to teratogenic factors may occur during the first few weeks and, by the time pregnancy is recognized, it is already too late. This represents an even bigger risk for women suffering from chronic pain.

The current use of some of the medications given to pregnant women with chronic pain is based on what is known from studies conducted in patients with depressive disorder or epilepsy. In these disorders, the risk of not using or discontinuing the medication is greater than that of using it. Unlike these conditions, neuropathic pain does not imply a major direct risk for the life of the patient, and the approach to treatment must be as safe as possible for the mother and the fetus. Moreover, the mother must play an active role in decision-making regarding her management and should be fully informed of the uncertainty that exists regarding many of the treatments available at the present time.

Teratogenicity and toxicity

When pregnancy is suspected, the first thing to do is to minimize the use of drugs and optimize non-pharmacological therapies, as long as it is possible. When the mother needs medication, the physician must be aware of the potential harmful effects for the mother, the fetus and the course of pregnancy.

Protein binding, liposolubility, molecular weight and the rate at which drugs are metabolized are all determinants of the degree to which they are present in placental and fetal circulation. Except for large molecules like insulin and heparin, for example, almost all medications cross to the placental circulation to a certain extent. The time of highest teratogenic risk is during organogenesis, between weeks 4 and 10. Before that time, there is an “all or none effect”, that is to say that the embryo dies (many times unnoticed), or pregnancy continues with no harm to the fetus. After week 10, drug effects may affect fetal organs, reduce the amount of amniotic fluid, generate IUGR, delay delivery, or trigger syndromes or create fetal pulmonary hypertension.

The US Food and Drug Administration (FDA) recommends a classification based on the studies available to determine drug risk versus benefit in pregnancy. Each medication is classified under one of five categories, according to the results of animal or human studies:

Category A: Adequate studies in pregnant women have not shown risk for the fetus in the first trimester of pregnancy and there is no evidence of risk later in pregnancy. Category B: Animal studies have not shown adverse effects on the fetus, but there are no adequate clinical trials in pregnant women. Category C: Animal studies have shown an adverse effect on the fetus, but there are no adequate clinical studies in pregnant women. The drug may be useful in pregnant women despite potential risks. Category D: There is evidence of risk for the human fetus, but potential benefits of use in pregnant women may be acceptable despite potential risks. Category X: Animal or human studies show fetal abnormalities, or the reports of adverse reactions indicate evidence of fetal risk. The risks involved are clearly greater than potential benefits.19

Each medication is classified individually and there may even be drugs of different categories in the same group (Table 1). However, due to the difficulty and the ethical implications of conducting trials in pregnancy, the FDA created a registry for the exposure to medication during pregnancy, and has proposed a new additional classification that considers four components: risk to the fetus, clinical considerations (risk of inadvertent exposure), decision to prescribe (indication and time during pregnancy), and data section (detailed discussion of the existing literature). To this effect, it is collecting information from women, companies or doctors about the effects perceived by the pregnant women when they were taking a medication. Existing registries include autoimmune diseases, asthma, cancer, epilepsy, HIV/AIDS, and transplants.19

Table 1.

Drug categorization according to fetal risk.

Medication  Category  Reference 
Amitriptyline  68 
5% Lidocaine patches  69 
Lidocaine infiltrations  69 
Bupivacaine  70 
Cyclobenzaprine  71 
Buprenorphine  72 
Bupropion  73 
Caffeine  74 
Topical capsaicin  75 
Carbamazepine  76 
Clonazepam  77 
Codeine  78 
Hydrocodone  79 
Dexamethasone  80 
Diazepam  81 
Diclofenac  82 
Ergot derivatives  83 
Duloxetine  84 
Fentanyl  85 
Fluoxetine  86 
Phenytoin  87 
Gabapentin  88 
Pregabalin  89 
Olanzapine  90 
Hydromorphone  91 
Sumatriptan  92 
Ibuprofen  93 
Imipramine  94 
Meperidine  95 
Naloxone  96 
Ketoprofen  97 
Lamotrigine  98 
Celecoxib  99 
Methadone  100 
Butorphanol  101 
Morphine  102 
Mefenamic Acid  103 
Meloxicam  C–Da  104 
Phenobarbital  28 
Naproxen  105 
Acetyl salicylic acid  106 
Oxcarbazepine  107 
Oxycodone  108 
Paracetamol  109 
Piroxicam  110 
Topiramate  111 
Flurazepam  112 
Remifentanil  113 
Sertraline  114 
Sodium divalproate  115 
Quazepam  116 
Tramadol  117 
Triamcinolone  118 
Hydrocortisone  119 
Botulinum toxin A  120 
Valproic acid  121 
Venlafaxine  122 
Desvenlafaxine  123 
Propranolol  124 
Metoprolol  125 
Atenolol  126 
a

Meloxicam before week 30 is category C, and category D after week 30.

Source: Authors based on cited references.

Australia has a different classification system (Table 2)20 that takes into consideration the known harmful events for the developing fetus, including birth defects, effects that may or may not be reversible, and problems later in life. Overdose and occupational exposure to medications are not taken into consideration, and the classifications as A, B1, B2, B3, C, D, and X are not hierarchical (Table 3).

Table 2.

Australian risk categories for drugs during pregnancy.a

Categories  Definition 
Medications taken by a large number of pregnant women and women of child bearing age, with no observation of a proven increased frequency of malformations or of other direct or indirect harmful effects on the human fetus. 
B1  Medications that have been used only by a limited number of pregnant women and women in child bearing age, with no observation of an increase in the frequency of malformations or other direct or indirect harmful effects on the human fetus. Animal studies have not shown evidence of an increased incidence of fetal damage. 
B2  Medications that have been used only by a limited number of pregnant women and women in child bearing age, with no observation of an increase in the frequency of malformations or other direct or indirect harmful effects on the human fetus. Animal studies are inadequate or may be missing, but existing data do not show evidence of an increased incidence of fetal damage. 
B3  Medications that have been used only by a limited number of pregnant women and women in child bearing age, with no observation of an increase in the frequency of malformations or other direct or indirect harmful effects on the human fetus. Animal studies have shown evidence of an increased incidence of fetal damage, and their significance is considered uncertain in human beings. 
Medications that, due to their pharmacological effects, have caused or are suspected to cause, harmful effects on the human fetus or the neonate, without causing malformations. Those effects may be reversible. 
Medications that have caused or are suspected of having caused or expected to cause a higher incidence of human fetal malformations or irreversible damage. These medications may also have adverse pharmacological effects. 
Drugs with a high risk of producing permanent fetal damage and that should not be used during pregnancy or when the possibility of pregnancy exists. 

Source: Taken with permission from the Australian categorisation system for prescribing medicines in pregnancy, 2011, Therapeutic Goods Administration, used by permission of the Australian Government<http://www.tga.gov.au/hp/medicines- pregnancy-categorisation.htm>.

a

All long-term use or high dose opioids given close to the end of pregnancy are considered category D by the FDA.

Table 3.

Australian categorization of medications according to teratogenic risk.

Medication  Category 
Alfentanil 
Amitriptyline 
Apomorphine 
Aspirin 
Bupivacaine 
Bupivacaine+epinephrine 
Buprenorphine 
Bupropion  B2 
Caffeine 
Topical capsaicin  No data available 
Carbamazepine 
Clonazepam 
Codeine 
Dexamethasone 
Diazepam 
Diclofenac 
Dihydroergotamine 
Duloxetine  B3 
Etoricoxib 
Fentanyl 
Fluoxetine 
Phenytoin 
Gabapentin  B1 
Hydrocortisone 
Hydromorphone 
Hyoscine butyl bromide  B2 
Ibuprofen 
Imipramine 
ACE inhibitors 
Ketamine 
Ketoprofen 
Labetalol 
Lorazepam 
Levetiracetam  B3 
Levobupivacaine  B3 
Lidocaine 
Mefenamic acid 
Meloxicam 
Morphine 
Naloxone  B1 
Naproxen 
Nitrous oxide 
Oxcarbazepine 
Oxycodone 
Paracetamol 
Paracetamol+codeine 
Parecoxib 
Piroxicam 
Pregabalin  B3 
Propofol 
Remifentanil 
Sertraline 
Sumatriptan 
Sulindac 
Tramadol 
Triamcinolone 
Botulinum toxin  B3 
Valproate 
Venlafaxine  B2 

Source: Authors.

It is worth noting that this is done for information purposes, and that data shown may vary based on the results of present or future research, and that medications may change category according to the reports. Consequently, the recommendation is to check the FDA or the Australian websites periodically for updates on adverse events, in order to reduce risks.20,21

The following are a few recommendations on the use of medications.

Non-steroidal anti-Inflammatory agents

The use of NSAIDS must be avoided in the first trimester because of the risk of miscarriage, and during the second and the third trimester because of the risk of oligohydramnios or premature closure of the ductus with an effect on fetal circulation.18,22Dipyrone, taken out from the US market, is still available in some European and Latin-American countries. It has been studied in Brazil with no association found with major fetal malformations, IUGR, intra-uterine death, or pre-term delivery.23–25 In contrast, in other studies it has been associated with Wilms tumors in children exposed in utero, and there are several case reports suggesting its association with oligohydramnios and closure of the ductus arteriosus when used in the third trimester.23–26

Low-dose (60–80mg/day) acetyl salicylic acid does not create an important risk for the mother or the fetus, but higher doses have been associated with a greater risk of intra-cranial hemorrhage in neonates born before week 35.27

Anti-epileptic agents

Anti-epileptic agents during pregnancy must be used at the lowest effective dose. There are known effects related to major (cardiac, urogenital, central nervous system, cleft lip and palate) and minor fetal malformations, IUGR, microcephaly, and cognitive deficits. They may produce harmful effects up until day 70 after conception.28,29

What is clear about these drugs is that the lowest effective dose should be used, and that mono-therapy is better than poly-therapy.

Valproic acid is contraindicated both as mono-therapy and as part of poly-therapy. The dose at which it is used is directly associated with the risk of fetal malformations. A dose greater than 1.1g/day has a 30% risk of malformations while the risk with a dose under 1.1g/day is less than 3.2%.30,31

Carbamazepine must be used as mono-therapy, and has not been associated with cognitive disorders. In studies with this medication, it was concluded that carbamazepine had the lowest risk, as mono-therapy, of producing major congenital malformations.32

Anticonvulsants such as topiramate have also been associated with the possibility of producing major malformations such as cleft lip and palate. Gabapentin has been associated with minor malformations and it is contraindicated with breastfeeding because 100% crosses into the milk. These two drugs have shown increased toxicity when they are part of poly-therapy. The most recent publications suggest that, more important than poly-therapy itself is to analyze what the drug combination is.13,33

Pregabalin is frequently used in chronic neuropathic pain, but there are no human studies that can help determine its safety in pregnancy. In rats, it has been associated with low weight fetuses and bone problems.32

Anti-depressants

Anti-depressants are used frequently in the treatment of chronic pain, either as adjuvants in analgesic management, or as primary treatment of the concomitant depression. In pregnant women, depression is found in up to 12% of the population.34

As far as tricyclic antidepressants (TCAs) are concerned, adverse side effects and the possibility of lethal overdosing are well known. In pregnancy, no direct association has been reported with fetal malformations, although there are reports of fetal withdrawal syndrome due to TCA suppression.35

Cyclobenzaprine is a tricyclic amine used as muscle relaxant. Its use has been authorized by the FDA for the short-term (maximum 2 weeks) symptomatic treatment of muscle spasm pain. Studies in rats and rabbits using doses 20 times higher than those used in humans did not produce effects on the fetus, but the lack of controlled trials in humans limits the routine use of this drug. It should be used only when the benefit outweighs the risk.36

A higher risk of heart disease has been reported with exposure to paroxetine.37,38 There are no human studies with duloxetine, although there are reports of neonatal withdrawal syndrome and serotoninergic syndrome in babies who have been exposed. No conclusions can be derived to date about safety in pregnant women.39

In recent publications, fluoxetine has not been associated with fetal malformations and, if well tolerated by the mother, its use could be less risky than discontinuation.

Among selective serotonin reuptake inhibitors (SSRIs), some authors suggest that sertraline is the safest due to its low levels in blood and mother's milk. Although there is an absolute risk of malformations, it is low when compared to other SSIRs.40

Opioids

Pregnant women receiving chronic opioid treatment should take the lowest effective dose or, if possible, discontinue its use. Opioids should never be discontinued abruptly because the ensuing withdrawal syndrome may produce uterine irritation and miscarriage or premature delivery.41,42

For opioid-dependent patients, weaning must be done using methadone of buprenorphine. Recent case series and one randomized clinical trial show some advantages of buprenorphine in terms of higher birth weight, lower prevalence and severity of the neonatal withdrawal syndrome and shorter hospital stay for the newborn. Another important finding is that the neonatal withdrawal syndrome is less when buprenorphine is started before delivery versus starting it in the post-partum period (26% vs. 60% respectively).43,44

There are reports of better neonatal results when opioids are weaned when they are in use for chronic treatment of pain than when it is a matter of addiction, in terms of less severe neonatal withdrawal syndrome and less effect on birth weight.45

In a case report about the analgesic management of a pregnant woman with upper limb compartmental syndrome, the patient received long-term morphine infusion. This treatment was associated with fetal cerebral and placental vasoconstriction, which improved after switching to a fentanyl infusion. Whenever opioid infusions are required, the suggestion is to use opioids lacking active metabolites.46,47

Reports on the use of fentanyl patches propose this as a treatment option during pregnancy and even while breastfeeding. However, it is important to note that neonatal withdrawal syndrome is still a problem.48

According to the FDA, most opioids are category B or C, but during pregnancy they become category D. The FDA classifies codeine in category C after a study with 563 pregnant women exposed to it during the first trimester found that 8 neonates had respiratory malformations. This figure is statistically significant.49 However, other reports that came later have not found that association, and in the Australian categories it is under category A.20

Meperidine must not be given in repeated doses because of normeperidine, a long half-life (18h) metabolite that accumulates after several doses and produces central nervous system excitation that results in manifestations such as myoclonus and generalized seizures.50 It is classified under category C.

Benzodiazepines

In the first trimester, benzodiazepines are associated with a higher risk of congenital malformations, with an association between diazepam and a higher risk of cleft lip and palate and congenital inguinal hernia.51

There are other reports where diazepam has not been found to increase those risks but the recommendation is not to use it because of this history. The use of benzodiazepines in the peripartum period may produce fetal hypothermia, hyperbilirubinemia and respiratory depression. Moreover, neonatal metabolism of these drugs is very slow, with metabolites having been found in the baby's circulation even up to 10 days after a single dose given to the mother during the peripartum period.

Because of all these reasons, the use of these drugs is not recommended during the first trimester, peripartum or breastfeeding.

Other transdermal therapies

Under the FDA classification, 5% lidocaine patches are category B. There are studies in rats with transdermal application of 30mg/kg of lidocaine, with no adverse effects for the fetus, but there are no human controlled trials to confirm this information. Consequently, this therapy must be used only when the practitioner considers that the benefit outweighs any risk.21

Interventional analgesia

We did not find reports of the use of infusion pumps or spinal stimulators in pregnancy. However, there are several reports of patients who became pregnant while wearing one of those devices for chronic pain control.Regarding these patients, it is important to remember that uterine growth and skin and soft tissue distension that occur during pregnancy might displace the devices and alter their optimal functioning. Moreover, the presence of these devices has not been associated with difficulty controlling pain during labor. There are reports of epidural catheter placement in a woman in labor with cervical spine stimulator, and a woman with intrathecal morphine pump infusion. In these two cases, the catheter was placed with no complication and there was adequate control of pain.52–54

Management of these patients must be initiated during prenatal control in order to find the cause that led to the placement of the device, the anatomical location, the exact course of the electrodes (nerve stimulator) or of the catheter (intrathecal therapy pump), and to make decisions together with the obstetrician and the gynecologist about the different analgesic/anesthetic management possibilities (neuroaxial or another technique), either for normal delivery or for C-section.52

As mentioned above, there are no adverse events from the application of single-dose local anesthetic and slow-release steroids. In some cases, an analgesic block may be indicated.

In interventional analgesia in the non-obstetrical population, most procedures are done under fluoroscopic guidance, and for this reason it is not recommended during pregnancy, and it is practically contraindicated in the first trimester. This requires the specialist to look for other alternatives to guide the procedures, including ultrasound and nuclear magnetic resonance. There are multiple reports in the literature of blocks guided by these two forms of imaging, with good results in terms of pain reduction.55

Radiofrequency is another procedure used often in the management of chronic pain. Since it does not require fluoroscopic guidance, it is safe for the fetus. There are case reports in the literature, in particular of ultrasound-guided radiofrequency in cardiac arrhythmogenic foci, where the benefit of the procedures outweighs any risk. Pain management studies should be done in pregnancy, which does not pose the same risk as cardiac arrhythmia.56

There are case reports of epidural infusions in pregnancy for periods of more than 72h in conditions of pubic symphysis or lumbosacral pain that did not respond to medical treatment.53,57

Physical therapy

Conditioning exercises and good posture are recommended in order to prevent low back pain.58 When pain is already present, there are reports of good results with relaxation exercises and education on sleeping positions.59

Aerobic exercises in water help improve pain because of reduced gravitational loads on maternal muscles.60

Regarding therapies based on massage, heat and cold, results are contradictory. There are case series reporting benefits, but a systematic review reported absence of strong evidence about the benefit of this therapy. Moreover, it is important to note that massage performed by people who are not qualified may be more risky.61

Transcutaneous electrical nerve stimulation (TENS) is also useful in localized muscle pain and it has no adverse effects on the fetus. It must be applied maintaining low current density and avoiding acupuncture points used for inducing labor.62 According to a Cochrane review, there is inconsistent and limited evidence to determine if it is useful as mono-therapy in low back pain.63 However, there is evidence that doing TENS is better than doing nothing in this form of pain.

Acupuncture

Acupuncture has proved to be useful in muscle skeletal pain during pregnancy. In general, at least six sessions are required in the hands of a specialist in acupuncture, always avoiding uterine and cervical reference points in order not to trigger labor.64 Acupuncture also appears to be useful in the management of tension headache.65

Botulinum toxin

There is good evidence regarding the use of botulinum toxin in myofascial pain syndrome, neuropathic pain and joint pain.66

The data available in the literature regarding the use of botulinum toxin in pregnancy are case reports of women who received the toxin without knowing that they were pregnant. There were no harmful effects for the fetus in these cases where the application occurred during the first trimester.67

Conclusions

It is important to remember that pain in pregnant women is not always obstetrical.

Pregnant women receiving treatment for chronic pain must continue to be treated, even during labor and delivery.

The comprehensive management of the conditions that may be a source of pain during pregnancy requires the use of medications that are not always 100% safe. Treatment must be multidisciplinary and humanized, bearing in mind the implications for the mother and the fetus.

Most of the medications and therapies used for the treatment of pain have not been tested in controlled trials during pregnancy. Existing data suggest that the use of any of them, even those classified under category B, must be weighed against the potential short- and long-term risk for the fetus. There are websites that can be used for registering adverse events from drugs during pregnancy; based on the entries, the risk categories are then updated. It is important to visit those websites periodically in order to learn about the potential risks when initiating or continuing any form of therapy. Aside from the teratogenic risk, it is important to consider the effects on fetal development during the rest of the pregnancy as well as during breastfeeding.

Funding

This review was financed with personal resources.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References
1
J.M. Ertresvag,J.A. Zwart,G. Helde,H.J. Johnsen,G. Bovim
Headache and transient focal neurological symptoms during pregnancy, a prospective cohort
Acta Neurol Scand, 111 (2005), pp. 233-237 http://dx.doi.org/10.1111/j.1600-0404.2005.00350.x
2
R.E. Nappi,F. Albani,G. Sances,E. Terreno,E. Brambilla,F. Polatti
Headaches during pregnancy
Curr Pain Headache Rep, 15 (2011), pp. 289-294 http://dx.doi.org/10.1007/s11916-011-0200-8
3
S.A. Contag,C. Bushnell
Contemporary management of migrainous disorders in pregnancy
Curr Opin Obstet Gynecol, 22 (2010), pp. 437-445 http://dx.doi.org/10.1097/GCO.0b013e3283404e06
4
M. Cassina,E. Di Gianantonio,I. Toldo,P.A. Battistella,M. Clementi
Migraine therapy during pregnancy and lactation
Expert Opin Drug Saf, 9 (2010), pp. 937-948 http://dx.doi.org/10.1517/14740338.2010.505601
5
V.E. Pennick,G. Young
Interventions for preventing and treating pelvic and back pain in pregnancy
Cochrane Database Syst Rev, 2 (2007), pp. CD001139 http://dx.doi.org/10.1002/14651858.CD001139.pub2
6
M.W. Smith,P.S. Marcus,L.D. Wurtz
Orthopedic issues in pregnancy
Obstet Gynecol Surv, 63 (2008), pp. 103-111 http://dx.doi.org/10.1097/OGX.0b013e318160161c
7
H.C. Ostgaard,G.B. Andersson,K. Karlsson
Prevalence of back pain in pregnancy
Spine (Phila Pa 1976), 16 (1991), pp. 549-552
8
H. Elden,H.C. Ostgaard,M. Fagevik-Olsen,L. Ladfors,H. Hagberg
Treatments of pelvic girdle pain in pregnant women: adverse effects of standard treatment, acupuncture and stabilising exercises on the pregnancy, mother, delivery and the fetus/neonate
BMC Complement Altern Med, 8 (2008), pp. 34 http://dx.doi.org/10.1186/1472-6882-8-34
9
L. Noren,S. Ostgaard,G. Johansson,H.C. Ostgaard
Lumbar back and posterior pelvic pain during pregnancy: a 3-year follow-up
Eur Spine J, 11 (2002), pp. 267-271 http://dx.doi.org/10.1007/s00586-001-0357-7
10
E. Vermani,R. Mittal,A. Weeks
Pelvic girdle pain and low back pain in pregnancy: a review
11
T. Torstensson,A. Lindgren,P. Kristiansson
Corticosteroid injection treatment to the ischiadic spine reduced pain in women with long-lasting sacral low back pain with onset during pregnancy: a randomized, double blind, controlled trial
Spine (Phila Pa 1976), 34 (2009), pp. 2254-2258
12
S.H. Garmel,G.A. Guzelian,J.G. D’Alton,M.E. D’Alton
Lumbar disk disease in pregnancy
Obstet Gynecol, 89 (1997), pp. 821-822
13
M.L. Haanpaa,G.K. Gourlay,J.L. Kent,C. Miaskowski,S.N. Raja,K.E. Schmader
Treatment considerations for patients with neuropathic pain and other medical comorbidities
Mayo Clin Proc, 85 (2010), pp. S15-S25 http://dx.doi.org/10.4065/mcp.2010.0468
14
R.V. Shah
The management of nonobstetric pains in pregnancy
Reg Anesth Pain Med, 28 (2003), pp. 362-363
15
M.R. Pyke,L.E. Shutt
The management of non-obstetric pains in pregnancy
Reg Anesth Pain Med, 28 (2003), pp. 54-57 http://dx.doi.org/10.1053/rapm.2003.50006
16
R.H. Ablove,T.S. Ablove
Prevalence of carpal tunnel syndrome in pregnant women
WMJ, 108 (2009), pp. 194-196
17
F. Turgut,M. Cetinsahinahin,M. Turgut,O. Bolukbasi
The management of carpal tunnel syndrome in pregnancy
J Clin Neurosci, 8 (2001), pp. 332-334 http://dx.doi.org/10.1054/jocn.2000.0761
18
J.B. Hardy
The Collaborative Perinatal Project: lessons and legacy
Ann Epidemiol, 13 (2003), pp. 303-311
19
U.S. Food and Drug Administration. Summary of proposed rule on pregnancy and lactation labeling. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093310.htm; 2009 [accessed 10.12.11].
20
Australian Department of Healt and Aging. Therapeutic Goods Administration. Prescribing medicines in pregnancy database. Available from: http://www.tga.gov.au/hp/medicines-pregnancy.htm; 2011 [accessed 01.12.11].
21
FDA U.S. Food and Drug administration. Available from: www.fda.gov; 2011 [accessed 20.09.11]
22
D.K. Li,L. Liu,R. Odouli
Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study
23
L. Arruza Gomez,A. Corredera Sanchez,J. Montalvo Montes,E. de Marco Guilarte,M. Moro Serrano
Intrauterine closure of the ductus arteriosus probably associated with the taking of metamizole during the third trimester
An Pediatr (Barc), 68 (2008), pp. 626-627
24
B. Bar-Oz,M. Clementi,E. Di Giantonio,R. Greenberg,M. Beer,P. Merlob
Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative study
Eur J Obstet Gynecol Reprod Biol, 119 (2005), pp. 176-179 http://dx.doi.org/10.1016/j.ejogrb.2004.07.004
25
T. da Silva Dal Pizzol,L. Schuler-Faccini,S.S. Mengue,M.I. Fischer
Dipyrone use during pregnancy and adverse perinatal events
Arch Gynecol Obstet, 279 (2009), pp. 293-297 http://dx.doi.org/10.1007/s00404-008-0707-3
26
C.R. Sharpe,E.L. Franco
Use of dipyrone during pregnancy and risk of Wilms’ tumor. Brazilian Wilms’ Tumor Study Group
Epidemiology, 7 (1996), pp. 533-535
27
T.J. Ives,R.S. Tepper
Drug use in pregnancy and lactation
Prim Care, 17 (1990), pp. 623-645
28
J. Anderson,C.C. Moor
Anti-epileptic drugs: a guide for the non-neurologist
Clin Med, 10 (2010), pp. 54-58
29
P.B. Pennell
Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?
30
J. Jentink,M.A. Loane,H. Dolk,I. Barisic,E. Garne,J.K. Morris
Valproic acid monotherapy in pregnancy and major congenital malformations
N Engl J Med, 362 (2010), pp. 2185-2193 http://dx.doi.org/10.1056/NEJMoa0907328
31
D.J. Chong,C.W. Bazil
Update on anticonvulsant drugs
Curr Neurol Neurosci Rep, 10 (2010), pp. 308-318 http://dx.doi.org/10.1007/s11910-010-0120-8
32
D.S. Hill,B.J. Wlodarczyk,A.M. Palacios,R.H. Finnell
Teratogenic effects of antiepileptic drugs
Expert Rev Neurother, 10 (2010), pp. 943-959 http://dx.doi.org/10.1586/ern.10.57
33
M.A. Rose,P.C. Kam
Gabapentin: pharmacology and its use in pain management
Anaesthesia, 57 (2002), pp. 451-462
34
S.M. Marcus,J.E. Heringhausen
Depression in childbearing women: when depression complicates pregnancy
Prim Care, 36 (2009), pp. 151-165 http://dx.doi.org/10.1016/j.pop.2008.10.011
35
C.M. Pariante,G. Seneviratne,L. Howard
Should we stop using tricyclic antidepressants in pregnancy?
36
flexeril drug information. Available from: www.rxlist.com; 2007 [accessed 20.09.10]
37
S. Gentile,M. Galbally
Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review
J Affect Disord, 128 (2011), pp. 1-9 http://dx.doi.org/10.1016/j.jad.2010.02.125
38
A.R. Scialli
Paroxetine exposure during pregnancy and cardiac malformations
Birth Defects Res A Clin Mol Teratol, 88 (2010), pp. 175-177 http://dx.doi.org/10.1002/bdra.20655
39
A. Einarson
Antidepressants and pregnancy: complexities of producing evidence-based information
CMAJ, 182 (2010), pp. 1017-1018 http://dx.doi.org/10.1503/cmaj.100507
40
B. Hackley
Antidepressant medication use in pregnancy
J Midwifery Womens Health, 55 (2010), pp. 90-100 http://dx.doi.org/10.1016/j.jmwh.2009.11.003
41
American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine
Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine
Anesthesiology, 112 (2010), pp. 810-833 http://dx.doi.org/10.1097/ALN.0b013e3181c43103
42
NOUGG. Canadian guideline for safe and effective use of opioids in chronic non-cancer pain. Available from: http://nationalpaincenter.mcmaster.ca/opioids/; 2010 [accessed 08.09.10].
43
J. Kakko,M. Heilig,I. Sarman
Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series
Drug Alcohol Depend, 96 (2008), pp. 69-78 http://dx.doi.org/10.1016/j.drugalcdep.2008.01.025
44
H.E. Jones,R.E. Johnson,D.R. Jasinski,K.E. O’Grady,C.A. Chisholm,R.E. Choo
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome
Drug Alcohol Depend, 79 (2005), pp. 1-10 http://dx.doi.org/10.1016/j.drugalcdep.2004.11.013
45
C. Sharpe,C. Kuschel
Outcomes of infants born to mothers receiving methadone for pain management in pregnancy
Arch Dis Child Fetal Neonatal Ed, 89 (2004), pp. F33-F36
46
L.R. Collins,R.W. Hall,N.K. Dajani,P.J. Wendel,C.L. Lowery,H.H. Kay
Prolonged morphine exposure in utero causes fetal and placental vasoconstriction: a case report
J Matern Fetal Neonatal Med, 17 (2005), pp. 417-421 http://dx.doi.org/10.1080/14767050500123996
47
J.P. Rathmell,C.M. Viscomi,I.M. Bernstein
Tratamiento del dolor durante el embarazo y la lactancia
Tratamiento practico del dolor, 3.ª ed., pp. 205
48
R.S. Cohen
Fentanyl transdermal analgesia during pregnancy and lactation
J Hum Lact, 25 (2009), pp. 359-361 http://dx.doi.org/10.1177/0890334409333475
49
J.P. Rathmell,C.M. Viscomi,M.A. Ashburn
Management of non-obstetric pain during pregnancy and lactation
Anesth Analg, 85 (1997), pp. 1074-1087
50
K.O. Hagmeyer,L.S. Mauro,V.F. Mauro
Meperidine-related seizures associated with patient-controlled analgesia pumps
Ann Pharmacother, 27 (1993), pp. 29-32
51
L. Rosenberg,A.A. Mitchell,J.L. Parsells,H. Pashayan,C. Louik,S. Shapiro
Lack of relation of oral clefts to diazepam use during pregnancy
N Engl J Med, 309 (1983), pp. 1282-1285 http://dx.doi.org/10.1056/NEJM198311243092103
52
J.L. Hanson,E.J. Goodman
Labor epidural placement in a woman with a cervical spinal cord stimulator
Int J Obstet Anesth, 15 (2006), pp. 246-249 http://dx.doi.org/10.1016/j.ijoa.2005.08.007
53
M. Khan,T. Mahmood
Prolonged epidural analgesia for intractable lumbo-sacral pain in pregnancy
J Obstet Gynaecol, 28 (2008), pp. 350-351 http://dx.doi.org/10.1080/01443610802048560
54
E. Matsumoto,K. Yoshimura,E. Nakamura,T. Hachisuga,M. Kashimura
The use of opioids in a pregnant woman with lumbar disc herniation: a case report
J Opioid Manag, 5 (2009), pp. 379-382
55
F.A. Desmond,D. Harmon
Ultrasound-guided symphysis pubis injection in pregnancy
Anesth Analg, 111 (2010), pp. 1329-1330 http://dx.doi.org/10.1213/ANE.0b013e3181f4814c
56
M.G. Bongiorni,A. Di Cori,E. Soldati,G. Zucchelli,L. Segreti,G. Solarino
Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy
Europace, 10 (2008), pp. 1018-1021 http://dx.doi.org/10.1093/europace/eun120
57
J.K. Scicluna,J.D. Alderson,V.J. Webster,P. Whiting
Epidural analgesia for acute symphysis pubis dysfunction in the second trimester
Int J Obstet Anesth, 13 (2004), pp. 50-52 http://dx.doi.org/10.1016/j.ijoa.2003.08.006
58
I.M. Mogren
Previous physical activity decreases the risk of low back pain and pelvic pain during pregnancy
Scand J Public Health, 33 (2005), pp. 300-306
59
J. Lile,J. Perkins,R.L. Hammer,P.V. Loubert
Diagnostic and management strategies for pregnant women with back pain
JAAPA, 16 (2003),
60
M. Kihlstrand,B. Stenman,S. Nilsson,O. Axelsson
Water-gymnastics reduced the intensity of back/low back pain in pregnant women
Acta Obstet Gynecol Scand, 78 (1999), pp. 180-185
61
B. Stuge,G. Hilde,N. Vollestad
Physical therapy for pregnancy-related low back and pelvic pain: a systematic review
Acta Obstet Gynecol Scand, 82 (2003), pp. 983-990
62
Coldron Y, Crothers E, Haslam J. ACPWH guidance on the safe use of transcutaneous electrical nerve stimulation (TENS) for musculosketal pain during pregnancy. Available from: http://www.oaa-anaes.ac.uk; 2007 [accessed 22.09.09].
63
A. Khadilkar,D.O. Odebiyi,L. Brosseau,G.A. Wells
Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain
Cochrane Database Syst Rev, (2008), pp. CD003008
64
N.K. Ternov,L. Grennert,A. Aberg,L. Algotsson,J. Akeson
Acupuncture for lower back and pelvic pain in late pregnancy: a retrospective report on 167 consecutive cases
Pain Med, 2 (2001), pp. 204-207
65
K. Linde,G. Allais,B. Brinkhaus,E. Manheimer,A. Vickers,A.R. White
Acupuncture for tension-type headache
Cochrane Database Syst Rev, (2009), pp. CD007587
66
E. Qerama,A. Fuglsang-Frederiksen,T.S. Jensen
The role of botulinum toxin in management of pain: an evidence-based review
Curr Opin Anaesthesiol, 23 (2010), pp. 602-610 http://dx.doi.org/10.1097/ACO.0b013e32833c3405
67
E. de Oliveira Monteiro
Botulinum toxin and pregnancy
Skinmed, 5 (2006), pp. 308
68
American Society of Health-System Pharmacists, Inc. Amitriptilyne hidrochloride. Available from: http://www.drugs.com/monograph/amitriptyline-hydrochloride.html; 2011 [accessed 23.12.11].
69
APP Pharmaceuticals L. Xylocaine. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2010/006488s074lbl.pdf; 2010 [accessed 24.12.11].
70
Hospira. Bupivacaine hydrochloride. Available from: http://www.dailymedplus.com/monograph/view/setid/02a845c3-4521-4926-e397-25ab536e7cf6; 2011 [accessed 24.12.11].
71
Keltman Pharmaceuticals Inc. Flexeril. Prescribing information. Available from: http://www.drugs.com/pro/flexeril.html; 2010 [accessed 23.12.11].
72
American Society of Health-System Pharmacists, Inc. Buprenorphine hydrochloride. Available from: http://www.drugs.com/monograph/buprenorphine-hydrochloride.html; 2011 [accessed 18.12.11].
73
GlaxoSmithKline. Wellbutrin. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf; 2011 [accessed 10.12.11].
74
American Regent I. Caffeine citrate. Prescribing information. Available from: http://www.drugs.com/pro/caffeine-citrate.html; 2011 [accessed 13.11.11].
75
Wolters Kluwer Health. Capsaicin. Prescribing information. Available from: http://www.drugs.com/ppa/capsaicin.html; 2009 [accessed 23.10.11].
76
Farkas R. Clinical review, Adverse events. Drug: Carbamazepine. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2007/016608s098,020712s029,021710_ClinRev.pdf; 2007 [accessed 15.05.10].
77
Teva Pharmaceuticals USA Inc. Clonazepam. Prescribing Information. Available from: http://www.drugs.com/pro/clonazepam.html; 2011 [accessed 25.12.11].
78
Roxane Laboratories I. Codeine sulfate. Prescribing information. Available from: http://www.drugs.com/pro/codeine-sulfate.html; 2009 [accessed 07.10.11].
79
Abbott Laboratories. Vicodin. Prescribing information. Available from: http://www.drugs.com/pro/vicodin.html#; 2011 [accessed 10.10.11].
80
Pfizer Laboratories Div Pfizer Inc. Dexamethasone sodium phosphate. Available from: http://www.drugs.com/pro/dexamethasone-sodium-phosphate.html; 2011 [accessed 12.10.11]
81
American Society of Health-System Pharmacists, Inc. Diazepam. Available from: http://www.drugs.com/monograph/diazepam.html; 2009 [accessed 12.10.11]
82
TEVA Pharmaceuticals USA Inc. Diclofenac. Prescribing information. Available from: http://www.drugs.com/pro/diclofenac.html; 2011 [accessed 12.10.11]
83
West-ward Pharmaceutical Corp. Ergotamine and Caffeine. Prescribing information. Available from: http://www.drugs.com/pro/ergotamine-and-caffeine.html; 2008 [accessed 12.10.11].
84
Eli Lilly and Company. Cymbalta. Prescribing information. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm255064.htm; 2011 [accessed 25.12.11].
85
Cephalon I. Actiq. Prescribing information. Available from: www.fda.gov/downloads/Drugs/DrugSafety/ucm085817.pdf; 2007 [accessed 23.12.11].
86
Eli Lilly and Company. Prozac. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2009/018936s075s077lbl.pdf; 2009 [accessed 28.12.11]
87
Pfizer. Dilantin. Medication guide. Available from: www.fda.gov/downloads/Drugs/DrugSafety/UCM283845.pdf; 2011 [accessed 10.08.11].
88
Pfizer. Neurontin. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s050,020882s035,021129s033lbl.pdf; 2011 [accessed 10.08.11].
89
Pfizer Inc. Lyrica. Medication guide. Available from: www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf; 2011 [accessed 11.03.12]
90
Eli Lilly and Company. Zyprexa. Prescribing information. Available from: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1-05%20(Zyprexa%20(olanzapine)%20Labeling).pdf; 2008 [accessed 25.12.11].
91
Purdue Pharma L.P. Dilaudid. Prescribing information. Available from: http://www.purduepharma.com/PI/prescription/DilaudidInjectionsPI.pdf; 2011 [accessed 10.12.11].
92
GlaxoSmithKline. Imitrex. Prescribing information. Available from: http://us.gsk.com/products/assets/us_imitrex_tablets.pdf; 2010 [accessed 10.10.11].
93
Polygen Pharmaceuticals LLC. Ibuprofen. Prescribing information. Available from: http://www.drugs.com/pro/ibuprofen.html; 2011 [accessed 20.10.11].
94
Lupin Pharmaceuticals Inc. Imipramine Pamoate. Prescribing information. Available from: http://www.drugs.com/pro/imipramine-pamoate.html; 2011 [accessed 20.10.11].
95
West-ward Pharmaceutical Corp. Meperidine Prescribing Information. Available form: http://www.drugs.com/pro/meperidine-injection.html; 2011 [accessed 20.10.11].
96
Hospira I. Naloxone. Prescribing information. Available from: http://www.drugs.com/pro/naloxone.html; 2011 [accessed 10.10.11].
97
H.J. Harkins Company I. Ketoprofen Prescribing information. Available from: http://www.drugs.com/pro/ketoprofen.html; 2011 [accessed 20.10.11].
98
Teva Pharmaceuticals USA Inc. Lamotrigine. Prescribing information. Available from: http://www.drugs.com/pro/lamotrigine.html; 2012 [accessed 03.10.11].
99
Pfizer. Celecoxib, Capsules. Medication Guide. Available from: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162532.pdf; 2006 [accessed 20.12.11].
100
Ascend Laboratories L. Methadone. Prescribing information. Available from: http://www.drugs.com/pro/methadone.html; 2012 [accessed 23.10.11].
101
Bedford Laboratories. Butorphanol Prescribing Information. Available from: http://www.drugs.com/pro/butorphanol.html; 2010 [accessed 10.12.11].
102
West-ward Pharmaceutical Corp. Morphine. Prescribing information. Available from: http://www.drugs.com/pro/morphine-injection.html; 2011 [accessed 23.10.11].
103
Lupin Pharmaceuticals Inc. Mefenamic Acid. Prescribing Information. Available from: http://www.drugs.com/pro/mefenamic-acid.html; 2011 [accessed 12.10.11].
104
International Labs I. Meloxicam. Prescribing information. Available from: http://www.drugs.com/pro/meloxicam.html; 2012 [accessed 12.12.11].
105
Roxane Laboratories I. Naproxen. Prescribing Information. Available from: http://www.drugs.com/pro/naproxen.html; 2010 [accessed 12.10.11].
106
Himprit Pharmachem Pvt Ltd. Aspirine. Prescribing information. Available from: http://www.drugs.com/pro/aspirin.html. 2010 [accessed 12.10.11].
107
Breckenridge Pharmaceutical I. Oxcarbazepine. Prescribing information. Available from: http://www.drugs.com/pro/oxcarbazepine.html; 2012 [accessed 12.10.11].
108
Purdue Pharma L.P. OxyContin. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2010/022272lbl.pdf; 2010 [accessed 23.12.11].
109
Acetaminophen information. Available from: www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm165107.htm; 2011 [accessed 12.10.11].
110
Teva Pharmaceuticals USA Inc. Piroxicam. Prescribing information. Available from: http://www.drugs.com/pro/piroxicam.html; 2011 [accessed 23.10.11].
111
Mylan Institutional Inc. Topiramate. Prescribing information. Available from: http://www.drugs.com/pro/topiramate.html; 2011 [accessed 14.10.11].
112
West-ward Pharmaceutical Corp. Flurazepam. Prescribing information. Available from: http://www.drugs.com/pregnancy/flurazepam.html; 2010 [accessed 19.12.11].
113
Bioniche Pharma USA LLC. Ultiva. Prescribing Information. Available from: http://www.drugs.com/pro/ultiva.html; 2009 [accessed 10.12.11].
114
Pfizer. Zoloft. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/019839s072s075s076,020990s033s036s037lbl.pdf; 2011 [accessed 20.12.11].
115
Aurobindo Pharma Limited. Divalproex Sodium. Prescribing Information. Available from: http://www.drugs.com/pro/divalproex.html; 2011 [accessed 12.10.11].
116
Wolters Kluwer Health. Quazepam. Available from: http://www.drugs.com/ppa/quazepam.html; 2009 [accessed 10.12.11].
117
Lachman Consultant Services Inc. Tramadol. Atachment C. Available from: www.fda.gov/ohrms/dockets/dailys/04/sep04/090804/04p-0405-cp00001-04-Attachment-C-vol1.pdf; 2004 [accessed 22.12.11].
118
Bristol-Myers Squibb Company. Kenalog. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/012041s038lbl.pdf; 2011 [accessed 23.12.11].
119
Pharmacia and Upjohn Company. Solu-Cortef prescribing information. Available from: http://www.drugs.com/pro/solu-cortef.html; 2010 [accessed 20.12.11].
120
American Society of Health-System Pharmacists, Inc. Botulinum toxin type A. Prescribing information. Available from: http://www.drugs.com/monograph/botulinum-toxin-type-a.html; 2011 [accessed 23.12.11].
121
Pliva Inc. Valproic Acid. Prescribing information. Available from: http://www.drugs.com/pro/valproic-acid-capsules.html; 2010 [accessed 10.12.11].
122
Wyeth Pharmaceuticals Inc. Effexor. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2006/020151s044,020699s071lbl.pdf; 2006 [accessed 23.12.11].
123
Wyeth Pharmaceuticals Inc. Pristiq. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2010/021992s017lbl.pdf; 2009 [accessed 22.12.11].
124
Wyeth Pharmaceuticals Inc. Inderal. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2010/018031s036lbl.pdf; 2011 [accessed 22.12.11].
125
Novartis Pharmaceuticals Corporation. Lopressor. Prescribing Information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2008/017963s062,018704s021lbl.pdf; 2008 [accessed 11.03.12].
126
AstraZeneca Pharmaceuticals LP. Tenoretic. Prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/018760s028lbl.pdf; 2011 [accessed 11.03.12].

Please cite this article as: Roberto Díaz R, Lopera Rivera A. Manejo del dolor no obstétrico durante el embarazo. Artículo de revisión. Rev Colomb Anestesiol. 2012;40:213–23.

Corresponding author at: Carrera 78B # 51 A 25, Medellín, Colombia.

Based on the paper that you have consulted please tell us the grade of agreement or disagreement to the following statements, where 1 is totally disagree and 5 totally disagree:

The content that I consulted shows a high scientific quality.

  • 1 - Strongly disagree
  • 2 - Disagree
  • 3 - Neither agree nor disagree
  • 4 - Agree
  • 5 - Strongly agree

The content that I consulted is useful to my professional and academic labors.

  • 1 - Strongly disagree
  • 2 - Disagree
  • 3 - Neither agree nor disagree
  • 4 - Agree
  • 5 - Strongly agree
Rev Colomb Anestesiol 2012;40:213-23 - Vol. 40 Num.3 DOI: 10.1016/j.rcae.2012.05.005